SCHOFIELD, Wis., Oct. 26, 2010 (GLOBE NEWSWIRE) -- PuraMed BioScience, Inc. (OTCBB:PMBS) announced today that it is building upon its recently launched print advertising campaign for its migraine medication LipiGesic™ M.
The advertisements will appear in a number of newspapers, which have a total circulation of over 1,000,000. The ads will be in a direct response format, which means they encourage readers to call in or log on to purchase LipiGesic™ M after reading the ad. Ads featuring LipiGesic™ M will appear in print as a "run of press" rather than an insert. "Run of press" ads maximize the opportunity for exposure, since they are contained alongside the editorial content of the newspaper.
Upon evaluating consumer response after the initial set of ads is published, PuraMed will identify markets with the best response rates. The Company will then explore adding 15-second radio spots in those markets while further newspaper ads are published. By both print and radio ads running simultaneously in the same market, there is a greater chance of increasing brand awareness.
"We look forward to the continuation of our print advertising campaign in a number of newspapers across the country," said PuraMed BioScience CEO Russell Mitchell. "By running radio ads along with the print advertisements, more people have the opportunity to learn about LipiGesic™ M and its benefits. By expanding upon our print campaign, we are continuing our strategy to introduce LipiGesic™ M to a broad audience before our national retail launch."
While announcing new advertising campaigns, the Company is continuing to identify national retail opportunities in order to prepare for the retail launch of LipiGesic™ M. PuraMed also anticipates the potential publication of the results of a clinical study of LipiGesic™ M, which can generate significant awareness and increase visibility of the product to both the medical community and the general public.
About PuraMed BioScience, Inc.:
PuraMed BioScience, Inc. engages in the research, development and marketing of non-prescription medicinal and healthcare products. In addition to its leading product LipiGesic™ M, which provides acute relief from migraine headaches, the Company also has plans to launch LipiGesic™ PM that provides a remedy for insomnia and other sleep disorders as well as LipiGesic™ H for common tension headaches. For more information on PuraMed, visit the Company website at , join the Company's group page on Facebook by searching "PuraMed BioScience" and follow the Company on Twitter at .
Forward Looking Statements: This news release contains forward-looking statements regarding PuraMed BioScience and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different than those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.
CONTACT: PuraMed BioScience, Inc. Russell Mitchell, Chairman and CEO 715-359-6373 rmitchell@PuraMedBioScience.com www.PuraMedBioScience.com Investor Awareness, Inc. Investor Relations: Tony Schor James Foy 847-945-2222 www.investorawareness.com North Shore Public Relations, Inc. Media Contact: Renae Placinski 847-945-4505 Renae@northshorepr.com www.northshorepr.com